Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06140524
Title A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)
Acronym LINKER-MGUS1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.